Brochure
More information from http://www.researchandmarkets.com/reports/1095799/
Strategies for Building Early-Stage Pharmaceutical Pipelines
Through External Sources
Description: Under tremendous pressure to refuel dwindling development pipelines and improve R&D
productivity, pharmaceutical companies are seeking external sources of products and innovation.
Biotech companies offer valuable technologies, targets, and compounds. Pharma companies best
able to access these assets and adopt new business and R&D models to develop them will be most
competitive.
Questions Answered in This Report
Pharmaceutical companies are seeking new ways to build early-stage pipelines.
- What strategies are available to companies to access early-stage products and technologies?
- What are the benefits and risks of these strategies?
- What factors drive decision making for choosing strategies?
External sources offer a variety of valuable early-stage assets.
- What types of assets are available for building early-stage pipelines?
- Which companies are the most useful sources of these assets?
- Which pharmaceutical companies are targeting particular types of companies and assets?
Recent high-value deals exemplify different strategies for accessing external sources for building up
early-stage pipelines.
- What corporate strategies do these deals serve?
- What are the structure and value of these deals?
- How do these deals illuminate current industry trends and opportunities in building early-stage
pipelines?
Scope
- The need for innovation in building early-stage pipelines: R&D spending versus productivity,
patent expirations, acquisition targets.
- Strategies for accessing innovation: Mergers and acquisitions (M&As), corporate partnerships,
academic collaborations.
- Strategies for building pipelines through partnering: Development compounds, novel targets,
technology platforms.
- Select deal highlights in building early-stage pipelines: Novel product classes, disease modifying
drugs, early-stage compounds, programs around novel targets, broad platform technologies,
proprietary platform technologies, technologies for drug repositioning, product class diversification.
- Technologies of interest: RNA interference (RNAi), microRNA, large molecules, biologics,
glycosylation, antisense, oligonucleotides, DNA vaccine immunotherapy, structure based drug
design, deuterium–based drugs.
- Industry outlook: Restructuring internal R&D, need for corporate partnerships, reallocation of R&D
resources, shifts in industry structure, novel ways to generate external innovation, corporate
venture capital.
Contents: Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Strategies for Accessing Innovation
- Mergers and Acquisitions
- Corporate Partnerships
- Academic Collaborations
Strategies for Building Early-Stage Pipelines Through Partnering
- Novel Targets
- Technology Platforms
Select Deal Highlights
- Genentech/Bayhill Therapeutics
- Boehringer Ingelheim/Vitae Pharmaceuticals
- GlaxoSmithKline/Concert Pharmaceuticals
- Sanofi -Aventis/Exelixis
- Wyeth/Santaris Pharma
- Alnylam/Takeda
- Merck/GlycoFi
Industry Outlook
Tables
1. Patent Expirations for Select Blockbuster Drugs
2. Select Recent Corporate Partnerships: Discovery and Preclinical
3. Select Corporate Partnerships: Early-Stage Clinical Development
4. Select Corporate Venture Capital Funds
Figures
1. R&D Spending vs. FDA New Molecular Entity Approvals, 1997-2008
2. Percentage of Unlicensed Products in Pipelines of Top Pharmaceutical Companies
3. Factors Influencing Early-Stage Pharma-Biotech Dealmaking
Ordering: Order Online - http://www.researchandmarkets.com/reports/1095799/
Order by Fax - using the form below
Order by Post - print the order form below and sent to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct.
Product Name: Strategies for Building Early-Stage Pharmaceutical Pipelines Through External
Sources
Web Address: http://www.researchandmarkets.com/reports/1095799/
Office Code: OC8HQOJOLPTQP
Product Format
Please select the product format and quantity you require:
Quantity
Electronic: EURO €1,706.00
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card: American Express
Diners Club
Master Card
Visa
Cardholder's Name
Cardholder's Signature
Expiry Date
Card Number
CVV Number
Issue Date
(for Diners Club only)
Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Please transfer funds to:
Pay by wire transfer:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World